French biotech Abivax has raised $920 million, providing enough cash to fund operations through 2029 and enabling a solo U.S. launch without needing a buyer.

Abivax has successfully raised $920 million after underwriters fully exercised their overallotment option, indicating strong investor demand.

Several companies, including AeroVironment, Abivax, Astera Labs, and Watts Water Technologies, are making significant moves in midday trading, capturing market attention.

Abivax (ABVX) stock saw a 16% increase, attributed to bargain-hunting activity by investors.

Abivax has announced its financial performance for the first quarter.

Financial analysts are reporting bright prospects for Abivax (ABVX), indicating potential for future growth and positive developments for the pharmaceutical company.

Abivax CEO stated to CNBC that the company is not rushing for a deal, confident that key June trial data will enable them to secure better terms for potential partnerships, amidst analyst speculation of a takeover, reiterating no urgency for deal-making ahead of the readout.

Abivax stock saw its gains reduced after the company denied speculation regarding a potential deal or collaboration with AstraZeneca.

An assessment of how Wall Street analysts are responding to recent data concerning Abivax, indicating a potential shift in the company's valuation.

Abivax SA has priced an upsized $800M ADS offering, while Arbor Realty Trust has priced an upsized $325M convertible notes offering.

ABIVAX (ABVX) has announced a $90 million agreement to repurchase royalty certificates. This financial move aims to optimize the company's capital structure and future revenue streams.

ABIVAX (ABVX) has announced the appointment of Michael Nesrallah as its new Chief Commercial Officer.

Abivax has announced its full-year financial results, providing an overview of the company's performance.

An analysis outlines two key reasons why Abivax stock is projected to achieve a tenfold increase in value by the year 2036.

This article provides an analysis of ABIVAX Société Anonyme's stock, evaluating its current performance and investment potential for investors.

Biopharmaceutical company Abivax has commenced an underwritten public offering aiming to raise $600 million, seeking to secure capital for its ongoing research and development initiatives.

Abivax (ABVX) has reported its financial results for the first quarter of 2026, indicating a cash runway that now extends through 2027. The report provides an update on the company's financial health and operational outlook.

Shares of French biotech company Abivax plummeted 32% following the release of new data from a trial of its lead drug for bowel disease.

Abivax (ABVX) is presented as one of the best up-and-coming stocks with the highest upside potential. The article explains the reasons behind its promising outlook.

ABIVAX SA (ABVX) experienced a significant surge in its stock value, increasing by 58% in the fourth quarter.

Eli Lilly is reportedly considering re-entering the bidding process for Abivax, contingent on whether AstraZeneca fails to meet its acquisition deadline.